The σ1 receptor is a poorly understood integral membrane protein expressed in most cells and tissues in the human body. It has been shown to modulate the activity of other membrane proteins such as ion channels and G protein-coupled receptors 1-4 , and ligands targeting the σ1 receptor are currently in clinical trials for treatment of Alzheimer's disease 5 , ischemic stroke 6 , and neuropathic pain 7 . Despite its importance, relatively little is known regarding σ1 receptor function at the molecular level. Here, we present crystal structures of the human σ1 receptor bound to the classical antagonists haloperidol and NE-100, as well as the agonist (+)-pentazocine, at crystallographic resolutions of 3.1 Å, 2.9 Å, and 3.1 Å respectively. These structures reveal a unique binding pose for the agonist. The structures and accompanying molecular dynamics (MD) simulations demonstrate that the agonist induces subtle structural rearrangements in the receptor. In addition, we show that ligand binding and dissociation from σ1 is a multistep process, with extraordinarily slow kinetics limited by receptor conformational change. We use MD simulations to reconstruct a ligand binding pathway that requires two major conformational changes. Taken together, these data provide a framework for understanding the molecular basis for agonist action at σ1.
phenyl rings), representing a minimal σ1-binding pharmacophore (Fig. 1a) 10 . Cloning of the σ1 receptor showed that it bears no similarity to any other human protein 11 . Instead, its nearest homolog is the yeast Δ8-Δ7 sterol isomerase, ERG2p, although the σ1 receptor itself has no detectable isomerase activity 11 . Human genetic data have linked point mutants in σ1 receptor to inherited motor neuron diseases [12] [13] [14] , and animal models implicate the receptor in Parkinson's disease 15 , addiction 16 , and pain 17 . A σ1 receptor antagonist is currently in clinical trials for the treatment of neuropathic pain 7 , and agonists are in clinical trials for Alzheimer's disease 5 and ischemic stroke 6 .
Despite its potential therapeutic relevance and a wealth of high-affinity ligands, surprisingly little is known about the molecular underpinnings of σ1 receptor function.
There is substantial evidence to suggest that the σ1 receptor serves as a modulator for other signaling pathway effectors 2, 3, 18 . Specifically, knockdown or antagonism of σ1 receptor can potentiate G-protein coupled receptor (GPCR) signaling 2, 3 , while agonists of the σ1 receptor result in an IP3 receptor-dependent intracellular calcium flux 19 and inhibition of sodium 18 and potassium 20, 21 channel currents. The σ1 receptor exists in multiple oligomeric states, and reports suggest agonists causes a shift to monomeric or low molecular weight species, while antagonists bias the receptor towards high molecular weight species 4, [22] [23] [24] . However, the dominant physiologically relevant oligomeric forms and the precise way in which oligomerization is tied to agonist binding are unknown.
We recently reported the first structures of the human σ1 receptor bound to two different ligands, PD 144418, an antagonist, and 4-IBP, a poorly characterized ligand of ambiguous efficacy class 25 . The receptor crystallized as a trimer, with each protomer showing a fold including a single transmembrane domain and a β-barrel flanked by α helices 25 (Fig. 1b, Fig. 1c , and Supplementary Fig. 1a ) While these initial results provided the first structural information on σ1 receptor, neither ligand is commonly used to study σ1 receptor function, and little functional data are available for either.
In order to understand the molecular basis for agonist activity at σ1, we pursued structural studies of three well-characterized classical ligands of the receptor: the antagonists haloperidol and NE-100, and the agonist (+)-pentazocine. Using the lipidic cubic phase method we determined X-ray crystal structures of the receptor in complex with these three compounds at resolutions of 3.1 Å, 2.9 Å, and 3.1 Å, respectively (Table 1 , Supplementary Fig. 2 ). 
Results

Structure of human σ1 receptor bound to antagonists
The structures of the σ1 receptor bound to the classical antagonists haloperidol and NE-100 are highly similar to each other and to our previously reported structures of σ1 bound to PD 144418 and 4-IBP 25 ( Supplementary Figures 1b-1e ). Both haloperidol and NE-100 include a shared simple pharmacophore (Fig. 1a) , and both adopt similar conformations in the ligand binding site ( Fig. 1d and 1e ). In each case, the ligand's positively charged nitrogen forms an electrostatic interaction with E172, and the rest of the molecule adopts a linear pose that fits within the space not occluded by the many bulky hydrophobic residues that line the interior of the σ1 binding pocket ( Fig. 1d and   1e ). In general, the longer of the two hydrophobic regions occupies the region of the βbarrel that is proximal to the membrane, near the space between helices α4 and α5 
Structure of the human σ1 receptor bound to an agonist
The structures above reveal the overall pose of ligands in the antagonist-bound σ1 receptor, confirming a highly conserved binding mode and receptor conformation even for chemically diverse antagonists. Next, we investigated the structure of the receptor bound to (+)-pentazocine at 3.1 Å resolution ( Fig. 2 , Table 1 , Supplementary   Figures 2d and 2e ). In general, the agonist-bound receptor crystallized similarly to antagonist-bound σ1, and the overall conformation of the receptor did not change significantly ( Fig. 2a ). The exception is a movement of helix α4, which shifts roughly 1.8 Å away from helix α5 in the (+)-pentazocine bound structure relative to the PD 144418bound structure (Fig. 2b) . This movement appears to be a consequence of the pose adopted by (+)-pentazocine, which occupies a different portion of the receptor binding pocket than the other ligands examined thus far ( Fig. 2b and 2c) . This difference in helix α4 position is also consistently observed in MD simulations (Fig. 2d ). In simulations of unliganded σ1, the helix adopts a similar position as when an antagonist is bound ( Fig.   2d ), also suggesting that the agonist is responsible for the conformational change. (+)pentazocine engages in an electrostatic interaction with E172, and site 2 is positioned similarly to those of the antagonists, but its nonlinear shape forces site 1 to occupy space closer to helix α4 and further from α5 relative to the antagonists. In order to prevent a steric clash between the aromatic ring of (+)-pentazocine's benzomorphan group and residue A185 in helix α4 ( Fig. 2c ), helix α4 must shift towards the membrane and away from the ligand. This movement creates a slightly larger gap between helices α4 and α5 in the (+)-pentazocine-bound structure relative to the antagonist-bound structures. In the two best-resolved protomers of the (+)-pentazocine-bound structures, two water molecules occupy the space normally occupied by a portion of the antagonist. 
Kinetic analysis of σ1 receptor ligand association and dissociation
As noted above, the ligand binding site of the σ1 receptor is sterically occluded, and so the receptor must undergo a conformational change to allow ligand entry and egress. Previous work has shown that (+)-pentazocine associates with the receptor slowly, but rate constants for association and dissociation were not determined 26 . In order to gain a better understanding of how ligands associate and dissociate with the σ1 receptor, we undertook an analysis of ligand binding kinetics using [ 3 H](+)-pentazocine and membranes prepared from Sf9 cells expressing σ1 receptor.
We began by measuring off rate at 37 °C and found it to follow a slow exponential decay with a half-life of over 200 minutes ( Supplementary Fig. 3a ). To obtain detailed association kinetics, we turned to a scintillation proximity assay (SPA), in which purified FLAG-tagged receptor was bound to YSi SPA beads coated with protein A and M1 αFLAG antibody. In this format, a single reaction can be monitored continuously at room temperature for an extended period ( Supplementary Fig. 3b ). The measured Kd in SPA experiments was indistinguishable from that measured in membrane binding experiments, suggesting that the receptor-ligand interaction is similar in both lipid membranes and in detergent ( Supplementary Fig. 3c ). These experiments showed that the association of [ 3 H](+)-pentazocine to the σ1 receptor was not monophasic, but could be well modeled by a two-step association model, in which a zero-order reaction is followed by a concentration-dependent association step ( Fig. 3a , 3b, and 3c). We also measured ligand dissociation in SPA format. In contrast to the association reaction, the dissociation data fit well to a simple monophasic dissociation curve ( Fig. 3c and Supplementary Fig. 3d ).
Interestingly, both the apparent koff and the kfast parameters for [ 3 H](+)pentazocine dissociation and association varied nonlinearly with concentration, indicative of cooperativity in ligand binding ( Supplementary Fig. 3e and 3f, Table 2 ). However, the Hill coefficient for ligand binding in equilibrium experiments is indistinguishable from 1 ( Supplementary Fig. 3g ). Therefore, the binding of (+)pentazocine to one σ1 monomer alters the rate of ligand binding to the next monomer, but must equally affect both on and off rates. Additionally, though the association curve for each individual concentration could be fit to a two-step exponential function, a simple two-state model is insufficient to account for the global data. This suggests that though there are at least two steps to ligand association with the σ1 receptor, there are probably additional steps or conformational states that are not accounted for with a simple twostep fit.
Since the rate-limiting step for [ 3 H](+)-pentazocine association was not dependent on ligand concentration, we suspected that this step represented a conformational change from a ligand-inaccessible to a ligand-accessible state. To test this hypothesis, we repeated the experiment with [ 3 H]haloperidol. The association of [ 3 H]haloperidol to the σ1 receptor was also poorly modeled by a one-step reaction, but fit well to a two-step model ( Supplementary Fig. 3h and 3i ). Additionally, the rate of the slow step was essentially identical for both [ 3 H]haloperidol and [ 3 H](+)-pentazocine (Table 2) , which is consistent with the conclusion that this step represents a conformational change intrinsic to the receptor that is ligand-independent. As seen with constant for the slow step for ligand association to the σ1 receptor in the biphasic fit. † kfast is the observed rate constant for the fast step in ligand association to the σ1 receptor in the biphasic fit. ‡ koff is the observed off rate for a given concentration in the SPA measurements, based on a monophasic fit.
Ligand binding pathway via molecular dynamics simulation
To better characterize the pathway of ligand binding and dissociation, we performed MD simulations of σ1 with the goal of characterizing possible conformational rearrangements that could expose the binding pocket. To reduce the computational complexity of the system, we simulated the σ1 monomer and used accelerated molecular dynamics, which applies a boost to dihedral energy minima in order to speed up observation of conformational changes 27 .
The σ1 monomer from the crystal structure was inserted into a hydrated lipid bilayer, with (+)-pentazocine removed from the binding pocket and placed in the water.
Using multiple rounds of simulation totaling over 110 μs, we were able to assemble a three-step binding pathway, with (+)-pentazocine reaching a bound state with an RMSD < 3 Å to the crystallographic pose ( Fig. 4a ).
This binding pathway requires two major conformational rearrangements in order for the pocket to become accessible to the ligand. First, the "lid" of the receptor opens, breaking backbone hydrogen bonds between Trp136 and Ala161. Next, the beta-barrel structure in the interior of the receptor separates, breaking backbone hydrogen bonds between Glu123 and Arg175 and exposing the binding pocket. The ligand enters through this opening near the membrane, and assumes a near-crystallographic pose as the protein closes around it ( Fig. 4b ).
Each of these rare conformational changes or binding events was observed multiple times in simulation. Interestingly, the beta-barrel separation that exposes the binding site was only observed in simulations where the receptor "lid" had already opened, suggesting that two sequential conformational changes may be necessary before the ligand can bind. The lid opening may be a prerequisite for further conformational change as it may perturb the internal hydrogen-bond network of σ1 so that larger rearrangements may occur. where the "lid" region then opens. Next, the interior of the receptor opens, and the ligand enters and binds through this opening. b. A simulation frame after the ligand has entered the binding pocket (tan), compared to a frame initiated from the crystal structure with the ligand bound (blue). Protein backbone is shown for the binding simulation in grey. Helix α4 is located at the top of the rendering.
Discussion
Antagonism or genetic ablation of σ1 receptor has analgesic effects in whole animals and humans 7, 17, 28 , and potentiates GPCR signaling in cells 2, 3 . In contrast, σ1
receptor agonists are usually defined by their ability to oppose the effects of agonists, and have been associated with cytoprotective effects [29] [30] [31] . Currently, the biochemical basis for agonism or antagonism at the σ1 receptor is largely unknown, which complicates the unambiguous assignment of efficacy class for σ1 ligands. The most well-documented biochemical difference between the two ligand classes is that antagonists increase the receptor's oligomeric state, while agonists decrease the oligomeric state 4, [22] [23] [24] . The structural data we present here show that these ligands occupy a different region of the binding pocket ( Fig. 2c and 2d ). Antagonists adopt a more linear pose, with the primary hydrophobic region of the molecule pointing towards the space between helices α4 and α5, while (+)-pentazocine's primary hydrophobic site points towards helix α4 (figures 2c and 2d). Presumably, structurally similar agonists like (+)-SKF-10,047 adopt a similar pose, accounting for their shared biological activities.
As a result of the steric constraints of agonists, most of helix α4 is forced to shift 1.1-1.8 Å away from helix α5 to accommodate the ligand. In our structure, this shift in α4
does not disrupt the oligomerization interface between individual protomers. However, if α4 were to move to a greater degree, it could disrupt the oligomerization interface. This is consistent with prior data, which suggest that σ1 receptor agonists bias the receptor towards lower molecular weight states, while antagonists bias it towards higher molecular weight states 4, [22] [23] [24] . Additionally, molecular modeling by Yano et al. predicted that (+)-pentazocine and other multimer-impeding ligands would occupy this space differentially from haloperidol and other multimer-promoting ligands 24 , which is consistent with our structural results. Importantly, crystallographic studies by necessity favor conformationally stable, low-energy states, and so the structures shown here may not represent a fully activated state of the receptor. Indeed, studies of G protein-coupled receptors bound to agonists often show inactive-state structures in the absence of G proteins or antibody fragment stabilizers 32 .
We have also shown by kinetic analysis that (+)-pentazocine associates with the σ1 receptor in at least two steps, with MD simulation suggesting a three-step process requiring two substantial conformational changes to the receptor. Ligand association and dissociation at the σ1 receptor is very slow, and the rate-limiting step is independent of ligand concentration. Though many groups have analyzed the effects of σ1 receptor ligands in cells, there is no standard incubation time for observing σ1-dependent effects of σ ligands. A brief survey of the literature reveals that when using σ1 receptor ligands in cellular or biochemical assays, incubation times and temperatures vary from room temperature for 20 minutes 33 to 37 °C incubation for up to 72 hours 31 . Ligand concentrations are sometimes nearly 10,000-fold over Kd [34] [35] [36] . Our data indicate that it can take 1.5 hours or longer to reach saturation at 37 °C, and at room temperature it can take nearly a day. Furthermore, since the rate-limiting step is concentrationindependent, high ligand concentrations cannot overcome the receptor's slow binding kinetics. Therefore, when ascribing the effects of σ1 receptor ligands to the σ1 receptor, one must ensure that sufficient time is allowed for the ligands to engage with the receptor. If effects are observed too quickly and are only observed at ligand concentrations that are vastly higher than Kd, then it is unlikely that the effects are σ1mediated.
We have shown that the agonist (+)-pentazocine adopts a binding pose in the σ1 receptor binding pocket that is different from that of antagonists, which tend to bind similarly to one another despite their chemical diversity. We have also demonstrated that ligands associate with the σ1 receptor very slowly and in multiple steps. Our simulations suggest that ligands enter the binding pocket through a dynamic opening that would be challenging to predict based on a single crystal structure.
However, the precise details of σ1 signaling in cells have yet to be determined.
While there are myriad proposed binding partners for the σ1 receptor 1, 3, 4, 19, 30 , the critical effectors of σ1 receptor signaling still need to be unambiguously established. Future work will need to focus on these functional questions in order to fully understand the function of the σ1 receptor and its potential as a therapeutic target.
Online Methods
Protein expression and purification
Human σ1 receptor and was expressed and purified in Sf9 cells in a manner similar to that described previously 25 . In brief, the receptor was cloned into pFastBac1
with an amino-terminal hemagglutinin signal sequence, followed by a FLAG epitope tag and a 3C protease cleavage site. The receptor was expressed in Sf9 cells (Expression Systems) using the FastBac baculovirus system (ThermoFisher). Cells were grown in a shaker at 27 °C and infected when they had reached a density of 4 x 10 6 cells/mL. After infection, the cells were allowed to grow for 48-52 h, at which point they were harvested for centrifugation. Pellets were stored at -80 °C until use. 
Crystallography and data collection
Purified σ1 receptor was reconstituted into lipidic cubic phase as described previously 25, 37 . . Data collection was performed as described previously 25 . The datasets for haloperidol-bound and (+)-pentazocine-bound σ1 receptor were obtained from single crystals, while the dataset for NE-100-bound σ1 receptor was obtained by merging partial datasets from seven crystals.
Data processing, structure refinement, and model building
Data were processed using XDS 38 . For the haloperidol and NE-100 bound complexes, scaling was done with XSCALE 38 . For the (+)-pentazocine-bound structure, scaling was done with Aimless 39 . Phases for all three structures were solved via molecular replacement, using PD144418-bound σ1 receptor (PDB ID: 5HK1) as a search model. Model building was done with Coot 40 , and refinement was performed in phenix.refine 41 . Following refinement, structures were evaluated with MolProbity 42 , and figures were prepared with PyMOL 43 . The SBGrid Consortium supported all crystallographic data processing, refinement, and analysis software 44 .
Preparation of membranes for radioligand binding
Membranes were prepared as described previously 45 , using a protocol adapted from that of Vilner et al. 46 . In brief, Sf9 cells expressing σ1 receptor were harvested by centrifugation and lysed by osmotic shock in a buffer containing 20 mM HEPES pH 7.5, 2 mM MgCl2,1:200,000 (v/v) benzonase nuclease (Sigma Aldrich), and cOmplete Mini EDTA-free protease inhibitor tablets (Sigma Aldrich). The lysates were homogenized using a glass dounce tissue homogenizer and then centrifuged at 48,000 x g for 20 min.
Following centrifugation, the membranes were resuspended in buffer containing 50 mM Tris pH 8.0 and cOmplete Mini EDTA-free protease inhibitor tablets (Sigma Aldrich).
The samples were spun down as before and resuspended in the same buffer. Next, the samples were homogenized using a needle and syringe. Protein content was determined using the DC protein assay (Bio Rad). Samples were aliquoted into 100 μL aliquots at protein concentrations of 10-20 mg/mL and flash frozen in liquid nitrogen. All samples were stored at -80 °C until use.
Saturation binding in Sf9 membranes
Saturation binding was performed as described previously 45 , using a method similar to that of Chu and Ruoho 47 . Briefly, membrane samples from Sf9 cells expressing wild-type or mutant σ1 receptor prepared as described above were thawed, homogenized with a syringe, and diluted in 50 mM Tris pH 8.0. Each reaction was 100 μL, with a final concentration of 0.025 mg/mL protein and the indicated concentration of
To assay nonspecific binding, equivalent reactions containing 2 μM haloperidol were performed in parallel. Samples were shaken at 37 °C for 90 minutes.
Afterwards, the reaction was terminated by massive dilution and filtration over a glass microfiber filter using a Brandel harvester. Filters were soaked with 0.3% polyethyleneimine (PEI) for at least 30 minutes before use. Radioactivity was measured by liquid scintillation counting.
Measurement of ligand dissociation in Sf9 membranes
Membrane samples prepared as described above were thawed, syringe Data analysis was performed using GraphPad Prism.
Scintillation proximity assay
All scintillation proximity experiments were performed using protein-A coated YSi scintillation proximity beads (PerkinElmer, RPN143 
Molecular dynamics simulations
MD simulations setup
Simulations of the σ1 receptor were based on either the (+)-pentazocine or haloperidol-bound crystal structures described in this manuscript. The receptor was simulated in four distinct conditions ( Supplementary Table 1 Five independent simulations were initialized from the final snapshot of the restrained equilibration for each condition (Supplementary Table 1 ). These simulations were conducted in the NPT ensemble at 310 K and 1 bar, using a Langevin thermostat and Monte Carlo barostat. In each of these simulations we performed 5 ns of unrestrained equilibration followed by 0.8 -6.7 μs production run. Simulations used periodic boundary conditions and a time step of 4.0 fs with hydrogen mass repartitioning. Bond lengths to hydrogen atoms were constrained using SHAKE. Nonbonded interactions were cut off at 9.0 Å, and long-range electrostatic interactions were computed using the particle mesh Ewald (PME) method with an Ewald coefficient β of approximately 0.31 Å and B-spline interpolation of order 4. The FFT grid size was chosen such that the width of a grid cell was approximately 1 Å. Accelerated molecular dynamics (aMD) was used to boost dihedral potential energies, with parameters ED=10427 and αD=170.
For condition C, the ensemble of simulations was periodically visualized for major conformational change in the protein, and new sets of 5-10 simulation replicates initialized from restart files corresponding to rare events, with velocities either retained or equilibration being performed once more ( Supplementary Table 1 )
MD simulation analysis protocols
Trajectory snapshots were saved every 200 ps during production simulations.
Trajectory analysis was performed using VMD and CPPTRAJ, and visualization performed using VMD.
